Applications of MR Finger printing derived T1 and T2 values in Adult brain: A Systematic review

F1000Research, Journal Year: 2025, Volume and Issue: 14, P. 54 - 54

Published: Jan. 9, 2025

Magnetic resonance imaging (MRI) is essential for brain imaging, but conventional methods rely on qualitative contrast, are time-intensive, and prone to variability. finger printing (MRF) addresses these limitations by enabling fast, simultaneous mapping of multiple tissue properties like T1, T2. Using dynamic acquisition parameters a precomputed signal dictionary, MRF provides robust, maps, improving diagnostic precision expanding clinical research applications in imaging. Database searches were performed through PubMed, Embase, Scopus, Web science identify relevant articles focusing the application MR adult brain. We utilized preferred reporting items systematic reviews meta-analysis guidelines extract data from selected studies. Nine included final review, with total sample size 332 participants. In healthy brains, notable regional, sex, age, hemispheric variations identified, particularly corpus callosum thalamus. effectively differentiated meningioma subtypes, glioma grades, IDH mutation status, T2 values providing predictive classification. metastases, significant relaxometry differences noted between normal lesional tissues. For sclerosis, correlated disability measures, distinguishing relapsing-remitting secondary progressive forms. traumatic injury, longitudinal T1 changes strongly recovery, surpassing values. The review highlighted MRD as groundbreaking technique that enhances neurological diagnosis simultaneously quantifying relaxation times. With reduced times, outperforms MRI detecting subtle pathologies, properties, reliable biomarkers.

Language: Английский

---

A Radiologist's Guide to IDH-Wildtype Glioblastoma for Efficient Communication With Clinicians: Part I-Essential Information on Preoperative and Immediate Postoperative Imaging

Korean Journal of Radiology, Journal Year: 2025, Volume and Issue: 26(3), P. 246 - 246

Published: Jan. 1, 2025

The paradigm of isocitrate dehydrogenase (IDH)-wildtype glioblastoma is rapidly evolving, reflecting clinical, pathological, and imaging advancements. Thus, it remains challenging for radiologists, even those who are dedicated to neuro-oncology imaging, keep pace with this progressing field provide useful updated information clinicians. Based on current knowledge, radiologists can play a significant role in managing patients IDH-wildtype by providing accurate preoperative diagnosis as well postoperative treatment planning including delineation the residual tumor. Through active communication clinicians, extending far beyond confines radiology reading room, impact clinical decision making. This Part 1 review provides an overview about neuropathological understand past, present, upcoming revisions World Health Organization classification. findings that noteworthy while communicating clinicians immediate glioblastomas will be summarized.

Language: Английский

---

PET imaging of gliomas: Status quo and quo vadis?

Neuro-Oncology, Journal Year: 2024, Volume and Issue: 26(Supplement_9), P. S185 - S198

Published: July 6, 2024

PET imaging, particularly using amino acid tracers, has become a valuable adjunct to anatomical MRI in the clinical management of patients with glioma. Collaborative international efforts have led development and technical guidelines for imaging gliomas. The increasing readiness statutory health insurance agencies, especially European countries, reimburse underscores its growing importance practice. Integrating artificial intelligence radiomics glioma may significantly improve tumor detection, segmentation, response assessment. Efforts are ongoing facilitate translation these techniques. Considerable progress computer technology developments (eg quantum computers) be helpful accelerate efforts. Next-generation scanners, such as long-axial field-of-view PET/CT improved image quality body coverage therefore expanded spectrum indications Neuro-Oncology whole spine). Encouraging results trials prompted tracers directing therapeutically relevant targets mutant isocitrate dehydrogenase) novel anticancer agents gliomas In addition, success theranostics treatment extracranial neoplasms neuroendocrine tumors prostate cancer currently translate this approach These advancements highlight evolving role Neuro-Oncology, offering insights into biology response, thereby informing personalized patient care. Nevertheless, innovations warrant further validation near future.

Language: Английский

---

[68Ga]Ga-FAPI PET/CT in brain tumors: comparison with [18F]F-FDG PET/CT

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Sept. 6, 2024

To investigate the feasibility of [

Language: Английский

---

FET PET-based target volume delineation for the radiotherapy of glioblastoma: A pictorial guide to help overcome methodological pitfalls

Radiotherapy and Oncology, Journal Year: 2024, Volume and Issue: 198, P. 110386 - 110386

Published: June 15, 2024

Language: Английский

---

Future Directions in the Treatment of Low-Grade Gliomas

The Cancer Journal, Journal Year: 2025, Volume and Issue: 31(1)

Published: Jan. 1, 2025

Abstract There is major interest in deintensifying therapy for isocitrate dehydrogenase–mutant low-grade gliomas, including with single-agent cytostatic dehydrogenase inhibitors. These efforts need head-to-head comparisons proven modalities, such as chemoradiotherapy. Ongoing clinical trials now group tumors by intrinsic molecular subtype, rather than classic risk factors. Advances imaging, surgery, and radiotherapy have improved outcomes gliomas. Emerging biomarkers, targeted therapies, immunotherapy, radionuclides, novel medical devices are a promising frontier future treatment. Diverse representation glioma research will help to ensure that advancements care realized all groups.

Language: Английский

---

Preoperative Diffusion Tensor Imaging and Neurite Dispersion and Density Imaging in Isocitrate Dehydrogenase-Mutant Grade 2 and 3 Gliomas: Definition of Tumor-Related Epilepsy and Predictive Factors of Seizure Outcomes Based on a Single-Center Retrospective Case Series

Neurosurgery, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 29, 2025

BACKGROUND AND OBJECTIVES: Understanding and managing seizure activity is crucial in neuro-oncology, especially for highly epileptogenic lesions like isocitrate dehydrogenase (IDH)-mutant gliomas. Advanced MRI techniques such as diffusion tensor imaging (DTI) neurite orientation dispersion density (NODDI) have been used to describe microstructural changes associated with epilepsy. However, their role tumor-related epilepsy (TRE) remains unclear. This study aims investigate the of DTI NODDI tumor-derived metrics defining TRE predicting postoperative outcomes patients undergoing surgical resection IDH-mutant grade 2 3 METHODS: was a single-center retrospective study. Preoperative parameters included fractional anisotropy mean diffusivity. index (NDI), index, free-water fraction (FWF). These were calculated within three volumes interest (fluid-attenuated inversion recovery [FLAIR] tumor volume, FLAIR peripheral zone, central zone [Fcz]) correlated presentation, type, control, which reported according Engel classification system. RESULTS: Fifty-seven this Increased NODDI-derived FWF-Fcz ( P = .031) NDI-Fcz .046) values preoperative generalized although only confirmed its statistical significance .047) multivariate analysis. Lower diffusivity-FLAIR volume poor control both univariate .015, .026) analyses .024, .036), while trend toward found between higher NDI-FLAIR worse .055). CONCLUSION: quantitative may define predict Notably, be independent predictors outcomes, presentation. Further research warranted validate our findings better understand underlying mechanisms driving TRE.

Language: Английский

---

An effective MRI perfusion threshold based workflow to triage additional 18F-FET PET in posttreatment high grade glioma

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 5, 2025

MRI is the preferred method for follow-up imaging of post-treatment WHO grade 3 or 4 gliomas. While positron emission tomography with O-(2-[18F]fluoroethyl)-L-tyrosine) (18F-FET PET) offers higher diagnostic accuracy, its use limited due to low availability. We propose a sequential, threshold-based workflow triage patients additional 18F-FET PET scans based on dynamic susceptibility contrast (DSC) perfusion-derived rCBV values, optimize resource allocation. Patients high-grade gliomas who had undergone standard-of-care treatment and developed new enlarging contrast-enhancing lesions were included, study performed within months MRI. excluded if there significant changes in lesion size between scan. An threshold was determined performance evaluated compared gold standard defined here as surgical verification long-term without further intervention. Forty-one total 49 included (tumor progression n = 40, treatment-related 9). Above 2.4, 100% accurate (21/21 patients) diagnosing tumor progression. Below threshold, identified 9 true negatives but produced 19 false negatives. reclassified 18/19 (95%) resulting an overall accuracy 48/49 (98%) workflow. Our DSC perfusion rCBV-based triaging high glioma has potential

Language: Английский

---

The Surgical Management of Cutaneous Melanoma

Dermatologic Clinics, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

---

Comparing the diagnostic performance of DSC-MRI and FAPI PET in differentiating tumor progression from treatment-related changes in IDH-Wildtype Glioblastoma: A pilot study

European Journal of Radiology, Journal Year: 2025, Volume and Issue: unknown, P. 112075 - 112075

Published: March 1, 2025

Language: Английский

---